EPC blends the interactivity characteristic of small regional conferences together with the cutting edge science characteristic of large national meetings. The educational goal is to share clinically relevant information which improves the diagnostic accuracy and the effectiveness of treatments with practitioners who treat pulmonary diseases.

On the agenda:

• Update on cough guidelines
• Molecular phenotyping of asthma
• Alarmins: Gateway to inflammation
• Treatment and “overtreatment” of hypoxemic respiratory failure
• Update on nosocomial pneumonia
• Liberation from mechanical ventilation in critically ill adults
• Antibiotic resistance: Issues for the intensivist and pulmonologist
• PBL – Uncontrolled asthma: Gaining control
• Pro/Con debate: Are short-acting beta agonists obsolete? The GINA Model
• Air travel and the pulmonary patient
• Hypersensitivity pneumonitis: Current concepts of pathogenesis & potential treatment targets
• Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
• Interstitial Lung Disease (ILD)
• Evolution of PF: From ILA’s to UIIP and everything in between
• Pro/Con: Redefining the diagnosis of COPD
• Lung nodules: Approaches to integrate imaging, biomarkers, risk and guidelines
• Resilience during the COVID -19 Pandemic
• THORACIC POCUS: Current trends and perspectives of point of care ultrasound
• COVID-19: Lessons clinicians have learned from the pandemic
• Advances in Nontuberculous Mycobacterial Lung Disease: Improvement in Diagnosis, Treatment and Patient Quality of Life
• Update on Anti-PD-1 Targeted Therapies for the Management of Patients with NSCLC
• Pulmonary Arterial Hypertension Management